A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Heard, Kennon ^a,b   Green, Jody L ^a,c   Anderson, Victoria ^a   Bucher Bartelson, Becki ^a,d   Dart, Richard C ^a,b  

^a ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF NURSING   (United States)

^d Global Health and Health Disparities   (United States)

Author keywords

Alanine aminotransferase; Drug induced liver injury; Hepatotoxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; PARACETAMOL; PLACEBO;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERTRANSAMINASEMIA; INTERNATIONAL NORMALIZED RATIO; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BLOOD; YOUNG ADULT;

ACETAMINOPHEN; ADULT; ALANINE TRANSAMINASE; FEMALE; HUMANS; MALE; PLACEBOS; YOUNG ADULT;

EID: 84924072470     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-39     Document Type: Article

References (28)

1. Dart RC, Bailey E: Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy 2007, 27:1219-1230
2. Harrill AH, Watkins PB, Su S, Ross PK, Harbourt DE, Stylianou IM, Boorman GA, Russo MW, Sackler RS, Harris SC, Smith PC, Tennant R, Bogue M, Paigen K, Harris C, Contractor T, Wiltshire T, Rusyn I, Threadgill DW: Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res 2009, 19:1507-1515
3. Heard K, Green JL, Bailey JE, Bogdan GM, Dart RC: A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther 2007, 26:283-290
4. Heard KJ, Green JL, Dart RC: Serum alanine aminotransferase elevation during 10 days of acetaminophen use in nondrinkers. Pharmacotherapy 2010, 30:818-822
5. Parra D, Beckey NP, Stevens GR: The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy. Pharmacotherapy 2007, 27:675-683
6. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, Harris SC: Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006, 296:87-93
7. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI: Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991, 325:87-91
8. Kuffner EK, Temple AR, Cooper KM, Baggish JS, Parenti DL: Retrospective analysis of transient elevations in alanine aminotransferase during long-term treatment with acetaminophen in osteoarthritis clinical trials. Curr Med Res Opin 2006, 22:2137-2148
9. Pincus T, Koch GG, Sokka T, Lefkowith J, Wolfe F, Jordan JM, Luta G, Callahan LF, Wang X, Schwartz T, Abramson SB, Caldwell JR, Harrell RA, Kremer JM, Lautzenheiser RL, Markenson JA, Schnitzer TJ, Weaver A, Cummins P, Wilson A, Morant S, Fort J: A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001, 44:1587-1598
10. Temple AR, Benson GD, Zinsenheim JR, Schweinle JE: Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther 2006, 28:222-235
11. Altman RD, Zinsenheim JR, Temple AR, Schweinle JE: Three-month efficacy and safety of acetaminophen extended-release for osteoarthritis pain of the hip or knee: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage 2007, 15:454-461
12. Prescott LF: Therapeutic misadventure with paracetamol: fact or fiction? Am J Ther 2000, 7:99-114
13. Gronbaek M, Becker U, Johansen D, Gottschau A, Schnohr P, Hein HO, Jensen G, Sorensen TI: Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann Intern Med 2000, 133:411-419
14. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf
15. Singer AJ, Carracio TR, Mofenson HC: The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction. Ann Emerg Med 1995, 26:49-53
16. Maheshwari A, Ray S, Thuluvath PJ: Acute hepatitis C. Lancet 2008, 372:321-332
17. Kechagias S, Ernersson A, Dahlqvist O, Lundberg P, Lindstrom T, Nystrom FH: Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 2008, 57:649-654
18. Sudano I, Flammer AJ, Periat D, Enseleit F, Hermann M, Wolfrum M, Hirt A, Kaiser P, Hurlimann D, Neidhart M, Gay S, Holzmeister J, Nussberger J, Mocharla P, Landmesser U, Haile SR, Corti R, Vanhoutte PM, Lüscher TF, Noll G, Ruschitzka F: Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010, 122:1789-1796
19. Narjes H, Nehmiz G: Effect of hospitalisation on liver enzymes in healthy subjects. Eur J Clin Pharmacol 2000, 56:329-333
20. Mitchell SJ, Hilmer SN, Murnion BP, Matthews S: Hepatotoxicity of therapeutic short-course paracetamol in hospital inpatients: impact of ageing and frailty. J Clin Pharm Ther 2011, 36:327-335
21. Lavonas EJ, Reynolds KM, Dart RC: Therapeutic acetaminophen is not associated with liver injury in children: a systematic review. Pediatrics 2010, 126:e1430-e1444
22. Senior JR: Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin Pharmacol Ther 2009, 85:331-334
23. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004, 126:1287-1292
24. Nolan CM, Goldberg SV, Buskin SE: Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999, 281:1014-1018
25. Pollak PT, Shafer SL: Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther 2004, 75:342-351
26. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271:992-998
27. Olsson R, Korsan-Bengtsen BM, Korsan-Bengtsen K, Lennartsson J, Waldenstrom J: Serum aminotransferases after low-dose heparin treatment. Short communication. Acta Med Scand 1978, 204:229-230
28. Tolman KG: The liver and lovastatin. Am J Cardiol 2002, 89:1374-1380